Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018

This study was supported by GlaxoSmithKline.

SN Westin funding: NIH SPORE for Ovarian Cancer (P50 CA083639), Andrew Sabin Family Fellowship (no grant number), GOG Foundation Scholar Investigator Award (no grant number), NCI (CA217685 and CA16672).

SN Westin reports personal fees from Agenus, GlaxoSmithKline, AstraZeneca, Circulogene, Roche/Genentech, Medscape, Clovis Oncology, Watermark Research Partners, Gerson Lehrman Group, Vaniam Group, Merck, Pfizer, BioAscend, Novartis, Takeda, Zentalis, Eisai; research support outside the submitted work from ArQule, AstraZeneca, Novartis, Bayer, GlaxoSmithKline, Cotinga Pharmaceuticals, Clovis Oncology, Roche/Genentech. PH Thaker reports personal fees and other from Stryker; personal fees from Celsion, GlaxoSmithKline, Clovis, AstraZeneca, AbbVie, Iovance Biotherapeutics, Genentech, Immunogen, Merck; research support from Merck and GlaxoSmithKline outside the submitted work. M Louie-Gao and D Gupta are current or former employees of GlaxoSmithKline. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Medical writing and editorial assistance, funded by GlaxoSmithKline (Waltham, MA) and coordinated by H Ostendorff-Bach of GlaxoSmithKline, were provided by N Renner and M Kacillas of Ashfield Healthcare Communications (Middletown, CT) and AM Schreiber of GlaxoSmithKline.

留言 (0)

沒有登入
gif